Eventide Asset Management LLC has recently announced that it has increased stake in Reneo Pharmaceuticals Inc (NASDAQ:RPHM) by 18.75%. After grabbing 2.08 million shares, the institutional investor is now in possession of 0.33 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 6.15% having worth around $16.81 million. Moreover, Franklin Advisers, Inc. increased its share by 0.15 million to have a control over 1.49 million shares. And Great Point Partners LLC raised its holdings to 83744.0 shares by acquiring 1.17 million shares or 3.45% of the stake.
Reneo Pharmaceuticals Inc (RPHM) concluded trading on 12/14/23 at a closing price of $1.34, with 26.08 million shares of worth about $34.95 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -81.34% during that period and on Thursday the price saw a loss of about -82.71%. Currently the company’s common shares owned by public are about 24.70M shares, out of which, 19.19M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 5 times over the past 12 months. They bought 140,625 shares in 2 of the transactions. In 3 selling transactions, insiders dumped 165,625 shares.
Eventide Healthcare & Life Scienc, FTIF SICAV – Biotechnology Discov, and Vanguard Total Stock Market ETF are the top 3 mutual funds which are holding stakes in Reneo Pharmaceuticals Inc Eventide Healthcare & Life Scienc is currently holding 2.08 million shares of worth totaling $16.81 million. The company recently came buying 0.33 million shares which brought its stake up to 6.15% of the company’s outstanding shares. FTIF SICAV – Biotechnology Discov bought 14000.0 shares, after which its hold over company’s outstanding shares expand to 3.02%, leaving 1.02 million shares with the mutual fund that have a worth of about $8.25 million. Vanguard Total Stock Market ETF, after buying 0.6 million shares, have now control over 1.76% of the stake in the company. It holds 0.0 shares of worth $4.82 million.
However, the stock later moved at a day high price of 1.6700, or with a loss of -82.71%. Stock saw a price change of -80.86% in past 5 days and over the past one month there was a price change of -78.86%. Year-to-date (YTD), RPHM shares are showing a performance of -42.49% which decreased to -36.49% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.88 but also hit the highest price of $11.30 during that period. The average intraday trading volume for Reneo Pharmaceuticals Inc shares is 211.47K. The stock is currently trading -79.72% below its 20-day simple moving average (SMA20), while that difference is down -81.52% for SMA50 and it goes to -81.14% lower than SMA200.
Eventide Asset Management LLC acquired 2.08 million shares of Reneo Pharmaceuticals Inc having value of about $16.81 million. Data submitted at the U.S SEC by Eventide Asset Management LLC revealed that the firm now holds 0.33 million shares in the company valued at close to $439710.28, or have control over 18.75% stake in the company. Reneo Pharmaceuticals Inc (NASDAQ: RPHM) currently have 24.70M outstanding shares and institutions hold larger chunk of about 42.04% of that. Holding of mutual funds in the company is about 23.51% while other institutional holders and individual stake holders have control over 27.19% and 17.91% of the stake respectively.
The stock has a current market capitalization of $44.64M and its 3Y-monthly beta is at 0.65. It has posted earnings per share of -$2.37 in the same period. It has Quick Ratio of 9.49 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RPHM, volatility over the week remained 20.26% while standing at 11.44% over the month.
Analysts are in expectations that Reneo Pharmaceuticals Inc (RPHM) stock would likely to be making an EPS of -$0.56 in the current quarter, while forecast for next quarter EPS is -$0.56 and it is -$2.32 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.63 which is -$0.37 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.56 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -13.59% while it is estimated to increase by 27.06% in next year.
